PRESS CENTER
新聞中心
News
-
2021/08/26Mycenax and Cytiva Enable First Continuous Manufacturing Process Development Satellite Laboratory in Taiwan
-
2021/06/08Mycenax signs an MOU with CHO PHARMA, cooperating to expand the production and application of next-generation antibodies
-
2021/05/28Mycenax becomes Taiwan’s first CDMO company to complete the CHO-S and CHOZN® GS Cell Line Development with the Beacon® Optofluidic System
-
2020/04/30Mycenax Announces the Sale of LusiNEX to Gedeon Richter
-
2020/02/20Mycenax signs agreement with Hummingbird Bioscience for production of anti-vista antibody HMBD-002 for cancer clinical trial.
-
2019/10/03Mycenax won the First Prize of Merck’s Advance Biotech Grant Program
-
2019/05/29Mycenax cooperates with Norwegian Vectron Biosolutions AS to create a high-volume microbiology platform for global CDMO
-
2019/03/12Mycenax Biotech Inc. has been shortlisted as a finalist in the CPhI Pharma Awards!
-
2019/03/12Mycenax Biotech Inc. announces TGA approval of phase I clinical trial authorization application for LusiNEX to treat aut
- 1
- 2